Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

Biotechnology Soap Opera: FDA, Sex, Politics, Religion

June 5, 2006

By Cynthia Robbins-Roth

High-Priced Drugs Causing Angst; Genzyme Stands Pat

May 22, 2006

By Cynthia Robbins-Roth

High-Priced Drugs Causing Angst; Genzyme Stands Pat

May 22, 2006

By Cynthia Robbins-Roth

How Frustrated Firm ReqMed Created New Biotech Strategy

May 8, 2006

By Cynthia Robbins-Roth

How Frustrated Firm ReqMed Created New Biotech Strategy

May 8, 2006

By Cynthia Robbins-Roth

How Juvaris Found New Path, Gathered Funds, Moved Ahead

April 24, 2006

By Cynthia Robbins-Roth

How Juvaris Found New Path, Gathered Funds, Moved Ahead

April 24, 2006

By Cynthia Robbins-Roth

Four Points Of Concern As Biotechnology Grows

April 10, 2006

By Cynthia Robbins-Roth

Four Points Of Concern As Biotechnology Grows

April 10, 2006

By Cynthia Robbins-Roth

Need Public Market Access? Go Knock On Heaven’s Door (Corp.)

March 27, 2006

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 4, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.